Threlfall, A.

screening cancer breast programme model breast cancer age range life years life year interval screening interval screen women death policy distribution stage screening programme breast cancer screening state effectiveness treatment koning hj breast screening programme range mortality amphotericin computer life histories modelled stage distribution effect toxicity van oortmarssen gj health result cost effectiveness phase koning screening policies amphotericin b number boer r patient university table invitation intralipid analysis cost effectiveness analysis computer modelled rates uk screening programme outcome population 27 years reduction prescreening stage distribution age 69 duration detection amphotericin b deoxycholate computer model department tumours diagnosis incidence conclusion history value glucose trial study measure benefit difference manchester paper utrecht professor www.bmj.com